Top View
- Actionable Targets by Tumor Genomic Profiling in Patients with Cholangiocarcinoma
- Enasidenib (IDHIFA) Criteria For
- Oncology Drug Reference Guide
- AG-221, a First-In-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
- Pharmacology Update
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Product Information for Enasidenib
- Pharmacy Medical Necessity Guidelines: Oral Cancer Medications Effective: August 16, 2021
- Preclinical Efficacy for a Novel Tyrosine Kinase Inhibitor, Arqule 531 Against Acute Myeloid Leukemia Ola A
- 2017 Notches up Some Landmark Approvals David M Mintzer, MD
- Cardiotoxicity of Novel Targeted Hematological Therapies
- Bristol Myers Squibb Compendium of Presentations Click on a Therapeutic Area to See a List of Scheduled Presentations
- Oncology Oral, Hematologic Cancers
- Shifting the Gears of Metabolic Plasticity to Drive Cell State Transitions in Cancer
- Oncology Center of Excellence 2020 Annual Report
- Therapeutic Advances in Oncology
- IDHIFA Safely None (4)
- Report Summary 4 Clinically Significant Variants & Combinations 1 Relevant Therapy 0 Other Biomarkers 2 Clinical Trials
- Leukemia Stemness and Co-Occurring Mutations Drive Resistance to IDH Inhibitors in Acute Myeloid Leukemia
- 2020 Medicines in Development ꟷ Cancer
- Idhifa) Reference Number: CP.PHAR.363 Effective Date: 09.05.17 Last Review Date: 11.20 Line of Business: Commercial, HIM, Medicaid Revision Log
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- AML Gemtuzumab Ozogamicin
- Management of Advanced Phase Myeloproliferative Neoplasms
- Pan-Canadian Oncology Drug Review Final Economic Guidance Report
- Emetogenic Potential of Antineoplastic Agents
- 209606Orig1s000
- Oncology Agents Policy #: Rx.01.67
- Applied Precision Cancer Medicine in Metastatic Biliary Tract Cancer
- List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
- Novel Therapies for Relapsed and Refractory Neuroblastoma
- Ptient-Assistance-And-Reimbursement
- Enasidenib Induces Acute Myeloid Leukemia Cell Differentiation to Promote Clinical Response
- Enasidenib (Idhifa) Reference Number: ERX.SPA.218 Effective Date: 09.05.17 Last Review Date: 11.18 Revision Log
- Understanding Your Diagnosis: Acute Myeloid Leukemia (Aml)
- IDHIFA (Enasidenib) Is an Inhibitor of Isocitrate Dehydrogenase-2 (IDH2) Enzyme
- List Item Minutes of the CHMP Meeting 27-29 May 2019 (PDF
- Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
- Ivosidenib (Tibsovo®); Enasidenib (Idhifa®) EOCCO POLICY
- Generic (Brand) Name Mechanism of Action Mechanism of Action
- Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients With
- Disease(S) Brand Name Drug Name Drug Company Phone Number Website Asparlas Calaspargase Pegol-Mknl Servier No Financial Assistan
- 409 Oncology Drugs
- Idhifa® (Enasidenib) (Oral) Document Number: IC-0313 Last Review Date: 07/03/2018 Date of Origin: 8/29/2017 Dates Reviewed: 08/2017, 07/2018
- Differentiation Syndrome Associated with Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2 Analysis of a Phase 1/2 Study
- Oncology Oral Medications Enrollment Form
- Master List of All CPT to Include Claims Only Codes for Any UM
- Hazardous Medication Precautions: Personal Protective Equipment (Ppe)
- Renal Impairment Hepatic Impairment Agent PK Summary Available
- Dose Recommendations for Anticancer Drugs in Patients with Renal Or Hepatic Impairment
- Discontinuation of Tyrosine Kinase Inhibitors in Patients with Chronic Myelogeneous Leukemia – You Can Do This at Home If You Read the Instructions Charles A
- Prior Authorization Criteria
- Oncology Oral-Hematologic
- Immunohistochemical Detection and Molecular Characterization of IDH-Mutant Sinonasal Undifferentiated Carcinomas
- 1 Widespread Reorganisation of the Regulatory Chromatin Landscape Facilitates Resistance to Inhibition of Oncogenic ERBB2 Signal
- Idhifa, INN-Enasidenib
- Enasidenib: a Magic Bullet for Myelodysplastic Syndromes?